Shares of Celgene Corp. fell in Monday's extended session after the drug maker decided not the pursue approval for use of Revlimid, a lymphoma drug, in maintenance therapy following a late stage study. The clinical study had evaluated the impact of Revlimid on survival rates along with a placebo. "The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the Revlimid arm," said Celgene in a statement. Celgene shed 2.4% after hours.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.